TimesSquare Capital Management LLC Acquires 42,015 Shares of Vericel Co. (NASDAQ:VCEL)

TimesSquare Capital Management LLC increased its holdings in Vericel Co. (NASDAQ:VCEL) by 7.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 632,160 shares of the biotechnology company’s stock after purchasing an additional 42,015 shares during the quarter. TimesSquare Capital Management LLC owned approximately 1.28% of Vericel worth $34,712,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. International Assets Investment Management LLC lifted its holdings in Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares during the period. Farther Finance Advisors LLC lifted its holdings in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 322 shares during the period. Meeder Asset Management Inc. acquired a new position in Vericel in the third quarter valued at $92,000. Finally, Geneos Wealth Management Inc. lifted its holdings in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,240 shares during the period.

Vericel Trading Up 0.3 %

Shares of NASDAQ VCEL opened at $57.28 on Wednesday. The firm’s 50-day moving average price is $57.82 and its 200-day moving average price is $51.41. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00. The firm has a market capitalization of $2.83 billion, a P/E ratio of 954.83 and a beta of 1.72.

Wall Street Analysts Forecast Growth

VCEL has been the topic of several recent analyst reports. BTIG Research boosted their target price on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Stephens restated an “overweight” rating and issued a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. Canaccord Genuity Group boosted their target price on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Truist Financial boosted their target price on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Wednesday, January 15th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $63.14.

Insider Activity

In other news, insider Jonathan Siegal sold 1,092 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the sale, the insider now directly owns 1,206 shares of the company’s stock, valued at $74,759.94. The trade was a 47.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the sale, the director now directly owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. The trade was a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,600 shares of company stock worth $1,356,072. Company insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.